|
|||||
|
|
| 中国非小细胞肺癌患者血清DAPK基因、p16基因启动子甲基化的分析 | |
| 引用本文： | 林勍,陈龙邦,唐永明,王晶. 中国非小细胞肺癌患者血清DAPK基因、p16基因启动子甲基化的分析[J]. 中德临床肿瘤学杂志, 2006, 5(3): 184-188. DOI: 10.1007/s10330-005-0430-5 |
| 作者姓名： | 林勍 陈龙邦 唐永明 王晶 |
| 作者单位： | [1]Department of Medical Oncology, Nanjing General Hospital of Nanjing Command, Nanjing 210002, China [2]Laboratory of Clinical Immunology, Nanjing 454th Hospital of Nanjing Air Force, Nanjing 210002, China |
| 基金项目： | 南京军区南京总医院科研项目 |
| 摘 要： | Objective： To evaluate the clinical significance of the aberrant methylation of DAPK gene and p16 gene in sera from 65 NSCLC patients from Nanjing General Hospital of Nanjing Command, China. Methods： A methylation-specific PCR （MSP） was performed for the detection of promoter hypermethylation of DAPK gene and p16 gene in blood DNA from 65 cases of NSCLC, and to analyze the relation of the aberrant methylation of DAPK gene and p16 gene and the clinicopathological data. Results： 30.8% （20/65） of the sera from 65 cases of NSCLC showed hypermethylation for DAPK promoter and 43.1% （28/65） the same for p16 promoter, whereas no methylated DAPK gene promoter and p16 gene promoter were found in sera from the patients with lung benign diseases and normal controls. Methylated DAPK gene promoter and p16 gene promoter in sera were not closely correlated with the pathological classification, stage, metastasis and differentiation in NSCLC. Conclusion： Detection of the aberrant methylation of DAPK gene and p16 gene in blood DNA from NSCLC patients might offer an effective means for the earlier auxiliary diagnosis of the malignancy. |
| 关 键 词： | 非小细胞肺癌 DAPK基因 p16基因 血清 DNA甲基化 |
| 收稿时间： | 2005-08-19 |
| 修稿时间： | 2006-03-28 |
The promoter hypermethylation of DAPK gene and p16 gene in sera from Chinese non-small cell lung cancer patients |
|
| Qing Lin,Longbang Chen,Yongming Tang,Jing Wang. The promoter hypermethylation of DAPK gene and p16 gene in sera from Chinese non-small cell lung cancer patients[J]. The Chinese-German Journal of Clinical Oncology, 2006, 5(3): 184-188. DOI: 10.1007/s10330-005-0430-5 | |
| Authors: | Qing Lin Longbang Chen Yongming Tang Jing Wang |
| Affiliation: | (1) Department of Medical Oncology, Nanjing General Hospital of Nanjing Command, Nanjing, 210002, China;(2) Laboratory of Clinical Immunology, Nanjing 454th Hospital of Nanjing Air Force, Nanjing, 210002, China |
| Abstract: | Abstract Objective To evaluate the clinical significance of the aberrant methylation of DAPK gene and p16 gene in sera from 65 NSCLC patients from Nanjing General Hospital of Nanjing Command, China. Methods A methylation-specific PCR (MSP) was performed for the detection of promoter hypermethylation of DAPK gene and p16 gene in blood DNA from 65 cases of NSCLC, and to analyze the relation of the aberrant methylation of DAPK gene and p16 gene and the clinicopathological data. Results 30.8% (20/65) of the sera from 65 cases of NSCLC showed hypermethylation for DAPK promoter and 43.1% (28/65) the same for p16 promoter, whereas no methylated DAPK gene promoter and p16 gene promoter were found in sera from the patients with lung benign diseases and normal controls. Methylated DAPK gene promoter and p16 gene promoter in sera were not closely correlated with the pathological classification, stage, metastasis and differentiation in NSCLC. Conclusion Detection of the aberrant methylation of DAPK gene and p16 gene in blood DNA from NSCLC patients might offer an effective means for the earlier auxiliary diagnosis of the malignancy. This project was supported by grants from the Scientific Research Foundation of Nanjing General Hospital of Nanjing Command (No. 2003017). |
| Keywords: | NSCLC DAPK gene p16 gene serum DNA methylation |
| 本文献已被 维普 万方数据 SpringerLink 等数据库收录！ | |